Irbesartan + Hidroclorotiazida Stada (Hydrochlorothiazide, Irbesartan)

Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptors on vascular smooth muscle and adrenal tissue. By preventing angiotensin II from binding, it inhibits vasoconstriction and aldosterone‑driven sodium retention, leading to relaxation of blood vessels and a reduction in systemic blood pressure.

The dose of Irbesartan + Hidroclorotiazida Stada is individualized by the prescribing clinician based on the patient’s blood pressure, renal function, and concomitant therapies. Healthcare professionals determine the appropriate strength and frequency, and patients should follow the prescriber’s instructions without altering the regimen.

Safety during pregnancy and lactation has not been established for this combination. It is generally avoided in pregnant women, especially during the second and third trimesters, because of potential fetal harm. Breastfeeding mothers should consult their healthcare provider, as the drugs may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Compared with monotherapy, the irbesartan‑hydrochlorothiazide combo offers synergistic blood‑pressure reduction by targeting both the renin‑angiotensin system and fluid volume. It often achieves target pressures at lower individual doses, potentially reducing side‑effect burden. Alternatives such as ACE inhibitors plus diuretics or calcium‑channel blocker‑based regimens provide similar efficacy, but the choice depends on patient comorbidities, tolerance, and clinician preference.

The product should be stored at ambient temperature, preferably below 25 °C, in the original blister or container to protect it from moisture and direct sunlight. Keep the tablets out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Irbesartan + Hidroclorotiazida Stada is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or split unless specifically advised. Consistent timing each day helps maintain stable blood‑pressure control.

Serious adverse events include severe dehydration, acute kidney injury, hyperkalemia, angioedema, and marked hypotension. Patients should be alert for symptoms such as sudden dizziness, swelling of the face or throat, rapid weight loss, reduced urine output, or muscle weakness, and seek immediate medical attention if any occur.

The combination is contraindicated in individuals with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation. It should also be avoided in patients with severe renal impairment, anuria, or those with a history of angioedema related to angiotensin‑targeting drugs. Clinicians must assess each patient’s medical history before prescribing.